MedTrace Logo

A Clinical Study To Investigate The Effectiveness And Safety Of Tanezumab In Treating Pain Associated With Endometriosis

NCT00784693 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2021-04-30

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether tanezumab is effective and safe in the treatment of pain associated with endometriosis.

Conditions

  • Endometriosis

Interventions

BIOLOGICAL

Tanezumab

15 mg IV single dose

DRUG

Placebo

Placebo IV single dose

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-12-18
Primary Completion
2010-01-27
Completion
2010-04-05

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00784693 on ClinicalTrials.gov